Abstract:Oral biotherapeutics hold significant promise, but their lack of controllability and targeting poses a major challenge, particularly for intestinal bacterial biotherapeutics. In response, we have developed a nanoencapsulation approach that responds to the release of enzyme activity in the organism and activates the enzyme in situ, allowing for controlled colonization of microbes in the gut. The nano-coating comprises a two-layer structure: an inner layer of polydopamine with photothermal and adhesive properties, and an outer layer of gelatin-sodium carboxymethylcellulose, which is hydrolyzed by cellulases in the gut following photothermal interaction with dopamine. We have successfully achieved controlled colonization of a wide range of microorganisms. Furthermore, in a diabetes model, this approach has had a profound impact on regulating glucagon-like peptide-1 (GLP-1) production, β-cell physiology, and promoting insulin secretion. This nanocoating is achieved by in situ activation of cellulase without the need for genetic or targeted molecular modification, representing a new paradigm and alternative strategy for microbial therapy. It not only enables precise and controlled colonization of probiotics but also demonstrates great potential for broader application in the field of oral biotherapy. STATEMENT OF SIGNIFICANCE: We have developed a nano-encapsulation method that triggers enzyme activity in response to enzymatic activity, resulting in the controlled release and adhesion of a wide range of microorganisms in the gut. The nano coating comprises two layers: an inner layer of polydopamine with photothermal and adhesion properties, and an outer layer of a gelatin-sodium carboxymethylcellulose polymer, which can be hydrolyzed by cellulases in the intestine. Additionally, this method allows for the preparation of various microbial coatings. This approach holds significant promise for regulating GLP-1 production, the physiological function of pancreatic β-cells, and promoting insulin secretion in diabetes models.

Biochemotaxis-Oriented Engineering Bacteria Expressing GLP-1 Enhance Diabetes Therapy by Regulating the Balance of Immune

Oral Delivery of Single-Chain Insulin (SCI-59) Analog by Bacterium-Like Particles (blps) Induces Oral Tolerance and Prevents Autoimmune Diabetes in NOD Mice.

The Oral Delivery System of Modified GLP-1 by Probiotics for T2DM.

Improvement effect of a next-generation probiotic L. plantarum-pMG36e-GLP-1 on type 2 diabetes mellitus via the gut-pancreas-liver axis.

Near-infrared remote triggering of bio-enzyme activation to control intestinal colonization by orally administered microorganisms

[Construction of Yeast Strains Expressing Long-Acting Glucagon-Like Peptide-1 (GLP-1) and Their Therapeutic Effects on Type 2 Diabetes Mellitus Mouse Model].

Remolding Probiotics for Effective Treatment of Type 2 Diabetes Via Oral Administration

Development of a C‐Terminal Site‐Specific PEGylated Analog of GLP‐1 with Improved Anti‐Diabetic Effects in Diabetic Mice

Heterologous Expression And Delivery Of Biologically Active Exendin-4 By Lactobacillus Paracasei L14

A micro-nano optogenetic system based on probiotics for in situ host metabolism regulation

Engineered Bacteria of MG1363-pMG36e-GLP-1 Attenuated Obesity-Induced by High Fat Diet in Mice

Expression and purification of optimized rolGLP-1, a novel GLP-1 analog, in Escherichia coli BL21(DE3) and its good glucoregulatory effect on type 2 diabetic mice.

Emerging Technologies to Achieve Oral Delivery of GLP-1 and GLP-1 Analogs for Treatment of Type 2 Diabetes Mellitus (T2DM)

Neuroprotective Effects of an Engineered Escherichia Coli Nissle 1917 on Parkinson's Disease in Mice by Delivering GLP‐1 and Modulating Gut Microbiota

Engineered Commensal Bacteria Reprogram Intestinal Cells Into Glucose-Responsive Insulin-Secreting Cells for the Treatment of Diabetes

Optogenetic operated probiotics to regulate host metabolism by mimicking enteroendocrine

A site-specific genomic integration strategy for sustained expression of glucagon-like peptide-1 in mouse muscle for controlling energy homeostasis.

A method for constructing GLP-1 overexpression intestinal organoids.

A engineered Bifidobacterium longum secreting a bioative penetratin-Glucagon-like peptide 1 fusion protein enhances Glucagon-like peptide 1 absorption in the intestine.

Recombinant Lactococcus Lactis Expressing Bioactive Exendin-4 to Promote Insulin Secretion and Beta-Cell Proliferation in Vitro

Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists